Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus XYLOCAINE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus XYLOCAINE W EPINEPHRINE.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs XYLOCAINE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Lidocaine blocks voltage-gated sodium channels, inhibiting neuronal depolarization and conduction. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging local anesthetic action.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
Adults: 1-5 mL of 1% or 2% solution (maximum 7 mg/kg lidocaine without epinephrine; 7 mg/kg with epinephrine; not to exceed 500 mg total) by infiltration or nerve block, not to be repeated within 2 hours.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Lidocaine terminal half-life: ~1.5-2 hours (initial); ~2-4 hours (terminal) after IV. Prolonged in hepatic dysfunction (up to 5-7 hours) and congestive heart failure (up to 10 hours).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Renal: lidocaine and metabolites (primarily 4-hydroxyxylidine and glycinexylidide) ~90% as metabolites, <10% unchanged. Biliary/fecal: minor (approximately 3-5%).
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist